A phase 3 clinical trial evaluating Vocacapsaicin for postsurgical pain
Latest Information Update: 26 Jul 2024
Price :
$35 *
At a glance
- Drugs Vocacapsaicin (Primary)
- Indications Postoperative pain
- Focus Registrational; Therapeutic Use
- Sponsors Concentric Analgesics
- 24 Jul 2024 According to a Concentric Analgesics media release, company plans to begin Phase 3 studies are largely completed and company remains deeply committed to bringing this innovative new treatment to patients and clinicians as quickly as possible.
- 02 Feb 2022 According to a Concentric Analgesics media release, announced a multi-faceted collaboration with the University of Rochester Medical Center (URMC). URMC will participate in the vocacapsaicin Phase 3 clinical trials.
- 02 Feb 2022 According to a Concentric Analgesics media release, company has entered into a formal agreement with Evolution Research Group (ERG), a leading postsurgical pain clinical research site network in the U.S., to conduct its registration trials.